Q-omics provides the consensus-scored SNX18P26 profile across patient tissues and cancer cell-line models. SNX18P26 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SNX18P26 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, SNX18P26 RNA expression shows 11,696 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, and THYM as cancer lineages where SNX18P26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX18P26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX18P26 survival associations across molecular data types. SNX18P26 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX18P26 RNA expression–survival associations across cancer types. High SNX18P26 expression shows unfavorable associations in KIRP, LUSC, LGG and SKCM, but favorable associations in CESC and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SNX18P26 RNA expression.
This table summarizes SNX18P26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNX18P26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX18P26 shows lower tumor expression in LUSC and higher tumor expression in KIRP, KIRC, LIHC, THCA and CHOL. The KIRP box plot shows higher SNX18P26 RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p = .001).
This table shows molecular features associated with SNX18P26 in patient tissues and cancer cell lines. In patient samples, SNX18P26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
